EP1858546A4 - Proteines hybrides modifiees de transferrine - Google Patents

Proteines hybrides modifiees de transferrine

Info

Publication number
EP1858546A4
EP1858546A4 EP06736868A EP06736868A EP1858546A4 EP 1858546 A4 EP1858546 A4 EP 1858546A4 EP 06736868 A EP06736868 A EP 06736868A EP 06736868 A EP06736868 A EP 06736868A EP 1858546 A4 EP1858546 A4 EP 1858546A4
Authority
EP
European Patent Office
Prior art keywords
fusion proteins
transferrin fusion
modified transferrin
modified
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06736868A
Other languages
German (de)
English (en)
Other versions
EP1858546A2 (fr
Inventor
Homayoun Sadeghi
Andrew J Turner
Christopher P Prior
David J Ballance
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biorexis Pharmaceutical Corp
Original Assignee
Biorexis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorexis Pharmaceutical Corp filed Critical Biorexis Pharmaceutical Corp
Publication of EP1858546A2 publication Critical patent/EP1858546A2/fr
Publication of EP1858546A4 publication Critical patent/EP1858546A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP06736868A 2005-03-04 2006-03-06 Proteines hybrides modifiees de transferrine Withdrawn EP1858546A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65814005P 2005-03-04 2005-03-04
US66375705P 2005-03-22 2005-03-22
PCT/US2006/007617 WO2006096515A2 (fr) 2005-03-04 2006-03-06 Proteines hybrides modifiees de transferrine

Publications (2)

Publication Number Publication Date
EP1858546A2 EP1858546A2 (fr) 2007-11-28
EP1858546A4 true EP1858546A4 (fr) 2009-03-04

Family

ID=36953883

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06736868A Withdrawn EP1858546A4 (fr) 2005-03-04 2006-03-06 Proteines hybrides modifiees de transferrine

Country Status (4)

Country Link
EP (1) EP1858546A4 (fr)
JP (1) JP2008531059A (fr)
CA (1) CA2599723A1 (fr)
WO (1) WO2006096515A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
EP2049560B1 (fr) 2006-07-13 2013-05-15 Novozymes Biopharma DK A/S Procédé de fabrication de particules d'un matériau protéique
KR101193722B1 (ko) 2006-07-24 2013-01-11 바이오렉시스 파마슈티칼 코포레이션 엑센딘 융합 단백질
WO2008021412A2 (fr) * 2006-08-14 2008-02-21 Biorexis Pharmaceutical Corporation PROTÉINES DE FUSION DE L'INTERFÉRON β ET DE LA TRANSFERRINE
ES2535358T3 (es) 2006-12-12 2015-05-08 Biorexis Pharmaceutical Corporation Bibliotecas de proteínas de fusión de transferrina
GB0711424D0 (en) * 2007-06-13 2007-07-25 Novozymes Delta Ltd Recombinant transferrin mutants
CA2695830A1 (fr) * 2007-08-08 2009-02-12 Novozymes Biopharma Dk A/S Variants de transferrine et conjugues
EP2195028A2 (fr) 2007-09-18 2010-06-16 The Jackson Laboratory Modifications d'anticorps et de protéines de fusion fc présentant une persistance accrue ou une stabilité pharmacocinétique<i>in vivo</i>et leurs procédés d'utilisation
DK3252068T3 (da) 2009-10-12 2025-08-25 Larry J Smith Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro
CA2784757A1 (fr) 2009-12-16 2011-07-07 Novo Nordisk A/S Derives a double acylation de glp-1
WO2012075037A1 (fr) 2010-11-30 2012-06-07 Genentech, Inc. Anticorps anti-récepteur de la barrière hémato-encéphalique à faible affinité et leurs utilisations
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
JP2014132832A (ja) * 2011-05-10 2014-07-24 Sekisui Chem Co Ltd 医薬、機能性食品、目的蛋白質の安定化方法、融合蛋白質、核酸、並びに、組換え体
US9434779B2 (en) 2012-03-19 2016-09-06 The Brigham And Women's Hospital, Inc. Growth differentiation factor 11 (GDF-11) for treatment of diastolic heart failure
EP4324475A1 (fr) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions de peptides glp-1 et leur préparation
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
HK1222331A1 (zh) 2013-03-12 2017-06-30 通用医疗公司 修饰的缪勒抑制物质(mis)蛋白及其用於疾病治疗的用途
JP6471385B2 (ja) 2013-03-15 2019-02-20 グラディエーター・バイオサイエンシーズ・インコーポレイテッド 標的化剤としてのＧｌａドメイン
US10092627B2 (en) 2013-04-08 2018-10-09 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
JP6618892B2 (ja) 2013-04-23 2019-12-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 細菌バイオフィルムの遺伝的リプログラミング
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
EP3007719B1 (fr) 2013-06-11 2021-03-17 President and Fellows of Harvard College Procédés et compositions pour augmenter la neurogenèse et l'angiogenèse
US11135269B2 (en) 2013-12-11 2021-10-05 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
CN106659758A (zh) 2014-06-02 2017-05-10 儿童医疗中心有限公司 用于免疫调节的组合物和方法
WO2016164422A2 (fr) * 2015-04-06 2016-10-13 President And Fellows Of Harvard College Matériaux biosynthétiques à base de substance amyloïde présentant des séquences de protéines fonctionnelles
WO2016210328A1 (fr) * 2015-06-24 2016-12-29 Board Of Regents Of The University Of Texas System Méthodes et compositions pour le traitement de symptômes associés à l'hémorragie intracrânienne
US11753633B2 (en) 2015-08-27 2023-09-12 President And Fellows Of Harvard College Compositions and methods for treatment of pain
US11098133B2 (en) 2016-05-19 2021-08-24 President And Fellows Of Harvard College Methods of making gels and films using curli nanofibers
WO2019014552A1 (fr) * 2017-07-14 2019-01-17 University Of Southern California Protéine de fusion d'insuline-transferrine et son promédicament, pro-insuline-transferrine, pour vaincre la résistance à l'insuline
WO2019149880A1 (fr) 2018-02-02 2019-08-08 Novo Nordisk A/S Compositions solides comprenant un agoniste de glp -1 et un sel d'acide n- (8- (2-hydroxybenzoyl) amino) caprylique
EP3810186B1 (fr) 2018-06-21 2022-09-28 Novo Nordisk A/S Nouveaux composés pour le traitement de l'obésité
CA3184852A1 (fr) 2020-07-10 2022-01-13 Lida Katsimpardi Utilisation de gdf11 pour diagnostiquer et traiter l'anxiete et la depression
WO2022057821A1 (fr) * 2020-09-16 2022-03-24 Suzhou Neologics Bioscience Co. , Ltd. Anticorps anti-pd-l1, protéines de fusion et leurs utilisations
US20240117033A1 (en) 2021-01-15 2024-04-11 President And Fellows Of Harvard College Methods and compositions relating to anti-mfsd2a antibodies
WO2025147573A2 (fr) 2024-01-05 2025-07-10 Immusoft Corporation Lymphocytes b modifiés exprimant le glp-1 pour le traitement d'une maladie métabolique
CN118460394B (zh) * 2024-07-12 2024-09-24 通化安睿特生物制药股份有限公司 一种用于制备转铁蛋白的工程菌及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO2006017688A2 (fr) * 2004-08-03 2006-02-16 Biorexis Pharmaceutical Corporation Polythérapie basée sur l’utilisation de protéines hybrides de transferrine contenant du glp-1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849293A (en) * 1996-01-11 1998-12-15 Cornell Research Foundation, Inc. Use of human transferrin in controlling insulin levels
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO2006017688A2 (fr) * 2004-08-03 2006-02-16 Biorexis Pharmaceutical Corporation Polythérapie basée sur l’utilisation de protéines hybrides de transferrine contenant du glp-1

Also Published As

Publication number Publication date
EP1858546A2 (fr) 2007-11-28
JP2008531059A (ja) 2008-08-14
WO2006096515A3 (fr) 2006-12-07
WO2006096515A2 (fr) 2006-09-14
CA2599723A1 (fr) 2006-09-14

Similar Documents

Publication Publication Date Title
IL189246A0 (en) Albumin fusion proteins
IL222924A0 (en) Albumin fusion proteins
IL196889A0 (en) Albumin-insulin fusion proteins
IL197580A0 (en) Albumin fusion proteins
PL1830872T3 (pl) Białka fuzyjne
GB0426397D0 (en) Fusion proteins
IL204839A0 (en) Albumin fusion proteins
ZA200709871B (en) Interferon-IgG fusion
IL196674A0 (en) Exendin fusion proteins
EP1889908A4 (fr) Protéine fusionnée possédant un anticorps anti-cd14
EP1934372A4 (fr) Proteines hybrides ssb-polymerase
IL198815A0 (en) Transferrin fusion protein libraries
ZA200801224B (en) Albumin fusion proteins
GB0514482D0 (en) Protein
EP1893635A4 (fr) Librairies de proteines de fusion transferine a ancrage
GB0725201D0 (en) Peptide fusion proteins
GB0700759D0 (en) Novel fusion protein
GB0511861D0 (en) Proteins
GB0522113D0 (en) vWFA-domain containing proteins
GB0426399D0 (en) Fusion proteins
GB0514481D0 (en) Proteins
GB0514788D0 (en) Proteins
GB0513505D0 (en) Proteins
AU2005905300A0 (en) Fusion Protein
GB0713169D0 (en) Fusion proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071004

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOREXIS PHARMACEUTICAL CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 20090130

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/76 20060101ALI20090126BHEP

Ipc: C12P 21/02 20060101ALI20090126BHEP

Ipc: C07K 14/605 20060101ALI20090126BHEP

Ipc: A61K 38/40 20060101ALI20090126BHEP

Ipc: A61K 38/26 20060101ALI20090126BHEP

Ipc: C12N 15/63 20060101ALI20090126BHEP

Ipc: C12N 15/12 20060101AFI20090126BHEP

Ipc: C12N 15/16 20060101ALI20090126BHEP

Ipc: C12N 5/10 20060101ALI20090126BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090418